From: Epidemiology and management of hepatitis C virus infections in immigrant populations
DAA regimen | HCV regions covered | HCV Genotype | Pill/day | Duration in weeks |
---|---|---|---|---|
Ombitasvir/paritaprevir/ritonavir/dasabuvir | NS3 + NS5A + NS5B | 1,4 | 4 | |
- Non cirrhosis | 8a | |||
- Cirrhosis | 12 | |||
Elbasvir/grazoprevir | NS3 + NS5A | 1,4 | 1 | 12b |
Sofosbuvir/velpatasvir | NS5A + NS5B | 1-6 | 1 | 12 |
Glecaprevir/pibrentasvir | NS3 + NS5A | 1-6 | 3 | |
- Non cirrhosis | 8 | |||
- Cirrhosis | 12 |